Guttate Psoriasis clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
Guselkumab Immunogenetics
open to eligible people ages 18 years and up
This is a two-arm open-label study to evaluate the clinical and immunogenetic responses of patients with plaque or guttate psoriasis to treatment with guselkumab.
at UCSF
Our lead scientists for Guttate Psoriasis research studies include Wilson Liao, MD.
Last updated: